

Ganesh Raghu, MD, ATSF , FACP ,FCCP.

August 2, 2024



Professor of Medicine

Professor of Laboratory Medicine and pathology (Adjunct),

Endowed Professorship Supporting Patients

with Interstitial Lung Disease in Honor of Ganesh Raghu, MD

University of Washington

Director, CENTER for Interstitial Lung Diseases (ILD), UW Medicine

Director, WASOG (World Association of Sarcoidosis and Other

Granulomatous disorders) CENTER for Excellence for Sarcoidosis

Director ,ILD/Sarcoidosis/Pulmonary fibrosis program

Co-Director, Scleroderma Clinic

University of Washington Medical Center-Montlake ,

Seattle, WA, USA

Professor Raghu received his medical degree from Mysore Medical College (batch of 1967), the University of Mysore, India, postdoctoral training in internal and chest medicine in the UK (Hartlepool General Hospital, affiliated with University of New Castle), residency in Internal medicine in USA (State University of New York at Buffalo, NY,USA) and fellowships in pulmonary diseases, critical care medicine and lung cell biology in USA(University of Washington, Seattle).

Dr. Raghu has had a longstanding clinical and scientific interest focused on pathogenesis, diagnosis and management of ILD, idiopathic interstitial pneumonia (IIP), Sarcoid, Rheumatological lung diseases, and idiopathic pulmonary fibrosis (IPF) in particular. He is an international authority in these disorders.

At the University of Washington(UW) Medical Center, he currently directs as well as directing the WASOG Center for Excellence for Sarcoidosis and Co- Director, Scleroderma clinic. He also served as the Director and Medical Director of the UW Lung transplant program that he initiated, developed and founded in 1991. Following the initiation and founding the UW's Center for ILD in 2013, he stepped down his administrative and leadership roles of the UW lung transplant program but continues to be the transplant pulmonologist for patients with ILD and remains an active member of the UW Lung transplant program.

He serves on several national and international committees for management of ILD and IPF as well as in the National Institute of health (NIH,USA) lung biology and pathology study section on an adhoc basis and several leadership roles. These include the Chair of international committee of IPF experts in developing and maintaining evidence based clinical practice guidelines for (1)2011, (2) 2015, (3)2018, (4)2022 diagnosis and management of IPF, (5)2022 diagnosis and management of progressive pulmonary fibrosis [sponsored by ATS-ERS-JRS-ALAT (American Thoracic Society, European Respiratory Society, Japanese Resp Society and Assoc.of Latin Am.Thoracic Society), (6) 2020 ATS Diagnosis of hypersensitivity pneumonitis,(7) 2024 ATS guideline on treatment for Systemic sclerosis associated Interstitial lung disease-SSc-ILD (8) Co-Chair on the 2012 ATS guideline clinical utility of Broncho alveolar lavage in the management of ILD (9) Co- chair on 2013 guideline on diagnosis and management of Bronchiolitis Obliterans syndrome following lung transplantation(joint sponsored by the

ATS/ERS/ISHLT(International Society of Heart and lung Transplant) (10) Co chair of the International Lung transplant committee provided a consensus statement on Chronic Lung allograft Dysfunction(CLAD), (11) an International committee member that originally wrote the original/first ATS document on classification of Idiopathic interstitial pneumonia (IIP) in 2002 and revised the classification of IIP(sponsored by the ATS and ERS). in 2013 and in the 2024 update classification on Interstitial pneumonia - work in progress and (12) recently chaired a committee that included leading international experts in the field and representatives from NIH, patients and patient advocacy organization that led to the published 2024 report on endpoints for IPF clinical trials(AJRCCM). He has also served as an adhoc advisory panel member for the division of Pulmonary, Allergy and Rheumatology of the Food and Drug Administration FDA(USA) and also serves on the scientific advisory board for the Pulmonary fibrosis foundation, USA .

Dr. Raghu's 40 years of research is devoted to both basic science (lung fibroblast and extracellular matrix) and translational and clinical studies in the field of pulmonary fibrosis, idiopathic interstitial pneumonias and sarcoid. Having conducted several prospective clinical studies and trials in IPF, and recently in pulmonary fibrosis associated with Scleroderma and sarcoidosis, he, along with other leading authorities, has provoked much awareness and interest for new treatment strategies based on the pathogenesis of pulmonary fibrosis. Among several research grants awarded to him and to his university from the NIH and the pharmaceutical industries to conduct IPF studies, he served in leadership roles in Clinical research network sponsored by the NIH – the IPFnet in USA and is an active and leading investigator of NIH funded ongoing clinical IPF trials besides serving leadership roles in the NIH studies and several pharma sponsored clinical trials .

Dr. Raghu has authored 400+ original articles, published in peer reviewed medical journals, and nearly 40 books/book chapters has altogether over 450 publications to date. He has served on editorial boards of several Respiratory Journals, currently serves on the editorial board of the *European Respiratory journal*, *American Journal of Respiratory and Critical Care Medicine* , as an advisory board member for *The Lancet-Respiratory Medicine* and is a frequent reviewer of manuscripts of original investigations submitted to many peer reviewed prestigious Respiratory journals AND journals for broad , general medical audience such as *The New England Journal of Medicine*, *Lancet*, and *JAMA*.

Above all, he is a longstanding patient advocate and actively sees and manages patients with ILD every week at the UW's Center for ILD, Seattle, WA, USA. He holds an "Endowed Professorship Supporting Patients with Interstitial Lung Disease in Honor of Ganesh Raghu, MD". He founded a pulmonary fibrosis support and education group in the Pacific northwest, USA in 1988, the first and the longest active group that meets every month at the UW Medical center and Dr Raghu attends this group meeting.

